Novartis (NVS) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2238956/novartis-nvs-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2238956
Mar 11, 2024 - Novartis (NVS) closed the most recent trading day at $101.37, moving +0.66% from the previous trading session.
0
What Makes Mainz Biomed NV (MYNZ) a New Buy Stock
https://www.zacks.com/stock/news/2238200/what-makes-mainz-biomed-nv-mynz-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2238200
Mar 08, 2024 - Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
0
bpost NV/SA (BPOSF) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4675447-bpost-nv-sa-bposf-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Mar 01, 2024 - bpost NV/SA (OTCPK:BPOSF) Q4 2023 Earnings Conference Call March 1, 2024 4:00 AM ETCompany ParticipantsChris Peeters - CEOPhilippe Dartienne - CFOConference...
0
Anheuser-Busch InBev/NV (BUD) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/02/29/anheuser-busch-inbevnv-bud-q4-2023-earnings-call-t/?source=iedfolrf0000001
Feb 29, 2024 - BUD earnings call for the period ending December 31, 2023.
0
Roche's (RHHBY) Xolair Gets Approval for Food Allergies
https://www.zacks.com/stock/news/2228151/roche-s-rhhby-xolair-gets-approval-for-food-allergies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2228151
Feb 19, 2024 - Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.
0
Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease
https://www.zacks.com/stock/news/2227293/ionis-ions-olezarsen-gets-fda-s-orphan-tag-for-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227293
Feb 16, 2024 - FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
0
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
https://www.zacks.com/stock/news/2225655/incyte-s-incy-q4-earnings-revenues-fall-shy-of-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2225655
Feb 13, 2024 - Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.
0
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline
https://www.zacks.com/stock/news/2225414/gilead-gild-to-buy-cbay-for-4-3b-add-pbc-drug-to-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225414
Feb 13, 2024 - Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
0
Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals
https://www.zacks.com/stock/news/2224190/pharma-stock-roundup-azn-lly-s-q4-earnings-nvo-nvs-mrk-s-m-a-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2224190
Feb 09, 2024 - Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.
0
KBC Group NV (KBCSY) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4668916-kbc-group-nv-kbcsy-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Feb 08, 2024 - KBC Group NV (OTCPK:KBCSY) Q4 2023 Earnings Conference Call February 8, 2024 3:30 AM ETCompany ParticipantsKurt De Baenst – Investor Relations ManagerJohan...
0